Evidence map›Paper›PMID 36610659›Full record

Trial reportInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2023

Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia.

Mahoko Ikeda, Shu Okugawa, Kosuke Kashiwabara, Takashi Moritoyo, Yoshiaki Kanno, Daisuke Jubishi, Hideki Hashimoto, Koh Okamoto, Kenji Tsushima, Yasuki Uchida and 27 more

Open access · goldAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. An orally available MNature communications · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 10 institutions in 1 country.

Mahoko IkedaDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan; Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan.
Shu OkugawaDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.
Kosuke KashiwabaraClinical Research Promotion Center, The University of Tokyo Hospital, Tokyo, Japan.
Takashi MoritoyoClinical Research Promotion Center, The University of Tokyo Hospital, Tokyo, Japan.
Yoshiaki KannoDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.
Daisuke JubishiDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.
Hideki HashimotoDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.
Koh OkamotoDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.
Kenji TsushimaDepartment of Pulmonary Medicine, International University of Health and Welfare, Narita Hospital, Chiba, Japan.
Yasuki UchidaDivision of Respiratory Medicine, Department of Internal Medicine, Shiga University of Medical Science, Shiga, Japan.
Takahiro MitsumuraDepartment of Respiratory Medicine, Tokyo Medical and Dental University Hospital, Tokyo, Japan.
Hidetoshi IgariDepartment of Infection Control, Chiba University Hospital, Chiba, Japan.
Takeya TsutsumiDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan; Division of Infectious Diseases, Advanced Clinical Research Center, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Hideki AraokaDepartment of Infectious Diseases, Toranomon Hospital, Tokyo, Japan.
Kazuhiro YateraDepartment of Respiratory Medicine, Hospital of the University of Occupational and Environmental Health, Fukuoka, Japan.
Yoshihiro YamamotoDepartment of Clinical Infectious Diseases, Toyama University Hospital, Toyama, Japan.
Yuki NakamuraRespiratory Center, Matsusaka Municipal Hospital, Mie, Japan.
Amato OtaniResearch Platform Office, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Marie YamashitaDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.
Yuji WakimotoDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.
Takayuki ShinoharaDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.
Maho Adachi-KatayamaDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.
Tatsunori OyabuDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.
Aoi KanematsuDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.
Sohei HaradaDepartment of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan.
Yuichiro TakeshitaDepartment of Pulmonary Medicine, International University of Health and Welfare, Narita Hospital, Chiba, Japan.
Yasutaka NakanoDivision of Respiratory Medicine, Department of Internal Medicine, Shiga University of Medical Science, Shiga, Japan.
Yasunari MiyazakiDepartment of Respiratory Medicine, Tokyo Medical and Dental University Hospital, Tokyo, Japan.
Seiichiro SakaoDepartment of Infection Control, Chiba University Hospital, Chiba, Japan.
Makoto SaitoDivision of Infectious Diseases, Advanced Clinical Research Center, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Sho OguraDepartment of Infectious Diseases, Toranomon Hospital, Tokyo, Japan.
Kei YamasakiDepartment of Respiratory Medicine, Hospital of the University of Occupational and Environmental Health, Fukuoka, Japan.
Hitoshi KawasujiDepartment of Clinical Infectious Diseases, Toyama University Hospital, Toyama, Japan.
Osamu HatajiRespiratory Center, Matsusaka Municipal Hospital, Mie, Japan.
Jun-Ichiro InoueResearch Platform Office, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yasuyuki SetoDepartment of Stomach and Esophageal Surgery, The University of Tokyo Hospital, Tokyo, Japan.
Kyoji MoriyaDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan; Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan. Electronic address: moriyakyojl0720@gmail.com.
University of Tokyo Hospital · JPChiba University Hospital · JPInternational University of Health and Welfare · JPShiga University of Medical Science · JPSoka Municipal Hospital · JPThe University of Tokyo · JPTokyo Medical and Dental University Hospital · JPToranomon Hospital · JPToyama University Hospital · JPUniversity of Occupational and Environmental Health Japan · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the efficacy and safety of nafamostat combined with favipiravir for the treatment of COVID-19.

methodsWe conducted a multicenter, randomized, single-blind, placebo-controlled, parallel assignment study in hospitalized patients with mild-to-moderate COVID-19 pneumonia. Patients were randomly assigned to receive favipiravir alone (n = 24) or nafamostat with favipiravir (n = 21). The outcomes included changes in the World Health Organization clinical progression scale score, time to improvement in body temperature, and improvement in oxygen saturation (SpO

resultsThere was no significant difference in the changes in the clinical progression scale between nafamostat with favipiravir and favipiravir alone groups (median, -0.444 vs -0.150, respectively; least-squares mean difference, -0.294; P = 0.364). The time to improvement in body temperature was significantly shorter in the combination group (5.0 days; 95% confidence interval, 4.0-7.0) than in the favipiravir group (9.0 days; 95% confidence interval, 7.0-18.0; P =0.009). The changes in SpO

conclusionAlthough our study showed no differences in clinical progression, earlier defervescence, and recovery of SpO

Indexed as

COVID-19AmidesAntiviral AgentsBenzamidinesDisease ProgressionGuanidinesHumansPyrazinesSARS-CoV-2Single-Blind MethodTreatment OutcomeAmidesAntiviral AgentsBenzamidinesfavipiravirGuanidinesnafamostatPyrazinesCOVID-19FavipiravirNafamostat mesilatePneumoniaSARS-CoV-2

Identifiers

PMID36610659
PMCPMC9810545
OpenAlexW4313594215

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.